Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Parnaparin→

Parnaparin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9041-08-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Low-molecular-weight heparin (LMWH)anticoagulant and antithrombotic
Mechanism of action
Binds antithrombin and accelerates inhibition of activated coagulation factor Xa, with a lower inhibitory effect on thrombin (factor IIa). Its anti-Xa activity exceeds its anti-IIa activity, as expected for this LMWH.
Indications / reported uses
  • Prevention and treatment of venous thromboembolic disorders in clinical settings covered by the locally authorised parnaparin product information; exact indication and dosing depend on formulation and jurisdiction.

Sources: https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Fluxum.pdf · https://meshb.nlm.nih.gov/record/ui?name=parnaparin · https://www.mhlw.go.jp/content/11120000/000904449.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Parnaparin Environmental Risk Assessment (ERA) (the Parnaparin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.